Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

Inclusion Criteria

• •Male or female subjects ages 21 to 75 inclusive. Female subjects must be of non-childbearing potential;
• •Has at the Screening Visit a serum uric acid ≥ 6 mg/dL, with or without a history of gout;
• •The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering therapy is permissible if dosing has been stable for at least the month prior to the Screening Visit
• •Has adequate venous access and able to receive IV therapy;
• •Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study;